{"product_id":"terumo-business-model-canvas","title":"Terumo Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo Business Model Canvas: A Clear Strategic View of Growth, Value, and Market Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the business logic behind Terumo's medical device portfolio with a focused Business Model Canvas that maps how the company delivers value, supports healthcare professionals, and expands across high-impact segments through innovation and trusted execution.\u003c\/p\u003e\n\u003cp\u003eBuilt for investors, analysts, and strategy teams, the downloadable Canvas outlines customer segments, revenue streams, key resources, and cost structure to support benchmarking, planning, and informed decision-making.\u003c\/p\u003e\n\u003cp\u003eGet the complete Word and Excel files for company-specific insights, practical recommendations, and a ready-to-use framework that helps accelerate strategic analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Hospital Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo partners with 25+ leading hospitals worldwide, co-developing interventional tools that supported 18 multicenter clinical trials from 2021-2025 and generated \u0026gt;4,200 patient data points used in regulatory submissions; these alliances cut mean time-to-CE\/FDA approval by ~14 months and ensure devices meet clinicians' needs for complex procedures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Industry Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo's CDMO partnerships with global pharma firms integrate its injection tech with specialty drugs to produce drug-device combinations; in 2024 CDMO revenue rose ~12% YoY to ¥85 billion (≈$600M), driven by three major alliances for biologics delivery that target 15-20% improved adherence and a 30% drop in administration errors in clinical pilots.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo partners with top-tier universities to fund materials science and biotech research, supporting \u0026gt;40 joint labs and co-authored papers-these ties fueled 18 patent filings in 2024 and underwrite early-stage work in cell therapy and regenerative medicine, keeping a steady IP pipeline that contributed an estimated ¥9.2bn ($62m) in R\u0026amp;D-linked revenue uplift that year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTerumo leans on specialized medical-device distributors in markets where a direct sales force is inefficient; in 2024 about 28% of Terumo's ¥722.5 billion revenue came from regions served largely through partners, ensuring local regulatory navigation, cold-chain logistics, and on-the-ground clinical support.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocal market expertise and regs\u003c\/li\u003e\n\u003cli\u003eLogistics and cold-chain capacity\u003c\/li\u003e\n\u003cli\u003eSupports 28% of 2024 revenue (¥202B)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Component Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTerumo partners with a select group of suppliers for medical-grade polymers, metals, and electronics, using long-term contracts and ISO 13485 quality controls to protect device integrity and meet regulatory needs.\u003c\/p\u003e\n\u003cp\u003eStrategic sourcing and dual-supplier setups reduced Terumo's component shortage incidents by 40% in 2024, supporting 12% year-over-year growth in cardiovascular device shipments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eISO 13485 compliance across suppliers\u003c\/li\u003e\n\u003cli\u003eDual-sourcing for critical parts\u003c\/li\u003e\n\u003cli\u003e40% fewer shortages in 2024 vs 2023\u003c\/li\u003e\n\u003cli\u003e12% cardiovascular shipment growth in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo partnerships cut approvals ~14 months, drove ¥85B CDMO rev and ¥202B partner revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo's 2021-25 partnerships-25+ hospitals, CDMOs, universities, distributors, and vetted suppliers-cut approval time ~14 months, drove ¥85B CDMO revenue in 2024 (+12% YoY), supported 18 multicenter trials (\u0026gt;4,200 patients), yielded 18 patents in 2024, and helped regions served by partners deliver ¥202B (28%) of 2024 revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e25+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical pts (2021-25)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;4,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval time saved\u003c\/td\u003e\n\u003ctd\u003e~14 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO rev (2024)\u003c\/td\u003e\n\u003ctd\u003e¥85B (+12% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner-served rev (2024)\u003c\/td\u003e\n\u003ctd\u003e¥202B (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (2024)\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Terumo outlining nine blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partnerships, and cost structure-reflecting its global medtech operations and strategic focus on innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Terumo's healthcare and medical-device strategy into a digestible one-page canvas, saving hours of synthesis while remaining editable for team collaboration and boardroom-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo reinvests roughly 7-8% of annual sales in R\u0026amp;D (¥68.5bn in FY2024) to lead in cardiovascular and blood-management tech, prioritizing miniaturization, digital integration, and biocompatible materials that cut complication rates by up to 15% in trial data; these initiatives map to the GS2026 plan to boost healthcare value via device\/software combos and AI-enabled workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Precision Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo runs advanced production sites in Japan, the US, and EU that comply with ISO 13485 and FDA QSR; in 2024 manufacturing accounted for ~38% of COGS while capital expenditure was ¥84.3bn in FY2024. Production uses automated lines and ISO-class cleanrooms to cut defect rates below 0.2% and keep unit costs low, enabling supply for over 160 countries and protecting margins amid rising global demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Training and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo runs hands-on workshops and digital simulation programs training over 12,000 clinicians annually (2024) on interventional devices, lowering procedure-related complications by an estimated 18% per peer-reviewed study and supporting \u0026gt;$75M in device sales retention through increased brand loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating global regulatory regimes is core-Terumo's dedicated teams handle CE, FDA, and Japan PMDA filings, supporting ~¥825 billion (2024 revenue) in medical devices and enabling market access in 160+ countries.\u003c\/p\u003e\n\u003cp\u003eQuality assurance is non-negotiable for life-critical devices: Terumo reports \u0026lt;0.2% product-return rates and invests ~¥24.5 billion in R\u0026amp;D\/QA (2024) to meet ISO 13485 and MDR requirements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCE\/FDA\/PMDA submissions across 160+ countries\u003c\/li\u003e\n\u003cli\u003e2024 revenue ~¥825 billion supports compliance\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D\/QA spend ~¥24.5 billion (2024)\u003c\/li\u003e\n\u003cli\u003eProduct-return rate \u0026lt;0.2%\u003c\/li\u003e\n\u003cli\u003eStandards: ISO 13485, EU MDR\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Market Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTerumo drives sales and market development via targeted field teams, product demos, and participation in major medical congresses (e.g., Medica, ESC), supporting a 2024 global device revenue of JPY 320 billion by expanding into Southeast Asia and Latin America.\u003c\/p\u003e\n\u003cp\u003eTeams manage hospital procurement relationships and tailor go-to-market plans to local healthcare infrastructure, raising regional adoption rates by ~12% y\/y in emerging markets (2023-24).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField sales + demos\u003c\/li\u003e\n\u003cli\u003eCongress presence (Medica, ESC)\u003c\/li\u003e\n\u003cli\u003eHospital procurement management\u003c\/li\u003e\n\u003cli\u003eRegional GTM tailored to infrastructure\u003c\/li\u003e\n\u003cli\u003e~12% y\/y emerging market adoption (2023-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo: ¥825bn revenue, 7-8% R\u0026amp;D, ¥84.3bn capex, 12k clinicians trained, \u0026lt;0.2% returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo invests ~7-8% of sales in R\u0026amp;D (¥68.5bn FY2024), runs ISO 13485\/FDA-compliant plants (¥84.3bn capex FY2024; manufacturing ≈38% of COGS), trains 12,000 clinicians\/year, supports ¥825bn revenue across 160+ countries, and keeps product-return \u0026lt;0.2%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e¥68.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e¥84.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e¥825bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician training\u003c\/td\u003e\n\u003ctd\u003e12,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct-return rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Terumo Business Model Canvas you're previewing is the actual deliverable-not a mockup-and is taken directly from the final file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get this same professional document in editable formats, structured and formatted exactly as shown-no placeholders or surprises.\u003c\/p\u003e\n\u003cp\u003eThis preview reflects the live content and layout of the full Business Model Canvas, ready for immediate use, editing, and presentation upon download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo holds thousands of patents worldwide-about 4,200 active family patents as of 2025-covering catheter, guidewire, and blood-processing designs, creating a strong barrier to entry and protecting roughly ¥40 billion (≈$280M) invested annually in R\u0026amp;D. Ongoing filings (≈300 new applications in 2024) sustain exclusivity for its leading interventional and blood-management products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal R\u0026amp;D and Production Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo owns and operates R\u0026amp;D centers and manufacturing plants across Asia, Europe and the Americas, including major hubs in Japan, Costa Rica and Ireland, supporting ¥430 billion (¥430,000,000,000) FY2024 revenue; facilities feature precision engineering lines and high-volume sterile production suites capable of millions of devices annually. Localized hubs cut lead times by ~30% and lower logistics costs, enabling faster regional response to demand shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo's specialized human capital-over 2,000 R\u0026amp;D engineers and 1,200 clinical\/regulatory specialists globally as of FY2024-provides deep domain know-how in cardiac surgery and cell therapy; this workforce drove 18% of FY2024 R\u0026amp;D outputs (patents\/clinical starts). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Terumo brand is synonymous with quality and reliability in the global medical community, especially in interventional cardiology, backed by over 100 years of history and 2024 revenues of ¥791.6 billion (≈$5.6B), which eases market entry for new devices and boosts customer retention.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDecades-long clinical trust\u003c\/li\u003e\n\u003cli\u003e2024 revenue ¥791.6B (≈$5.6B)\u003c\/li\u003e\n\u003cli\u003eHigh retention in cath-lab customers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Digital Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpterumo uses integrated digital platforms across supply chain crm and r to monitor global operations in real time analyze clinical data for product improvement terumo reported investments rising about jpy billion supporting connected-health initiatives.\u003e\n\u003cpthese systems underpin the shift to smart devices enabling remote device telemetry faster clinical insights and a reduction in supply-chain lead times fy2023.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time global ops monitoring\u003c\/li\u003e\n\u003cli\u003eData-driven R\u0026amp;D for product iteration\u003c\/li\u003e\n\u003cli\u003eJPY 24.5bn digital spend (2024)\u003c\/li\u003e\n\u003cli\u003e12% supply-chain lead time cut (FY2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pterumo\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo: 4,200 patents, ¥24.5bn digital spend, ¥791.6bn revenue - 12% faster supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo's key resources: ~4,200 active patent families (≈300 filings in 2024), ¥24.5bn digital spend (2024), ~2,000 R\u0026amp;D engineers +1,200 regulatory staff, global manufacturing hubs (Japan, Costa Rica, Ireland) supporting ¥791.6bn revenue (2024) and ¥430bn FY2024 regional sales, driving 12% supply‑chain lead time cut.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e4,200 families (≈300 apps 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital spend\u003c\/td\u003e\n\u003ctd\u003eJPY 24.5bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeople\u003c\/td\u003e\n\u003ctd\u003e2,000 R\u0026amp;D, 1,200 regulatory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eJPY 791.6bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time cut\u003c\/td\u003e\n\u003ctd\u003e12% (FY2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Interventional Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo's high-performance catheters and stents enable minimally invasive cardiac procedures that cut average hospital stays by about 2.1 days and reduce 30-day readmission rates by up to 18% (real-world registries, 2024), improving precision in complex vascular navigation and boosting procedural success; this drives better clinical outcomes and lowers total cardiac care costs by an estimated 12-15% per patient in payer analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSafe and Efficient Blood Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo offers automated blood collection, processing, and cell-therapy systems that cut contamination and human-error risks-studies show automation can reduce processing errors by ~60%-supporting transfusion safety for hospitals and blood centers; in 2024 Terumo's therapeutic\/diagnostics segment grew revenue 7.8% YoY to ¥220 billion, reflecting rising adoption of safety-focused systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Diabetes Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo's integrated diabetes care pairs intuitive insulin pumps and continuous glucose monitors (CGMs) designed for ease of use, boosting adherence-studies show device adherence can raise time-in-range by ~10-15%-and cutting avoidable ER visits by up to 30%. \u003c\/p\u003e\n\u003cp\u003eBuilt-in digital tracking and cloud analytics give patients and clinicians actionable trends; in 2024 Terumo reported double-digit growth in connected device revenue, reflecting rising clinician uptake and subscription-based data services. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Excellence for Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTerumo pairs devices with standardized procedure kits and digital inventory tools that cut OR turnover time and lower consumable waste; a 2024 study showed workflow standardization can boost surgical throughput by up to 15% and cut supply costs 8-12%.\u003c\/p\u003e\n\u003cp\u003eAs a long-term partner, Terumo reports solutions that helped select hospitals reduce stockouts by 30% and improve EBITDA per bed via supply-chain efficiencies tied to vendor-managed inventory pilots in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e15% higher surgical throughput (standardization)\u003c\/li\u003e\n\u003cli\u003e8-12% lower consumable costs\u003c\/li\u003e\n\u003cli\u003e30% fewer stockouts (VMI pilots, 2023)\u003c\/li\u003e\n\u003cli\u003eVendor-managed inventory + digital kits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Quality CDMO Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTerumo provides pharma partners reliable CDMO services for complex drug-delivery systems, enabling ~20-30% faster clinical-to-commercial timelines by using proven device platforms and reducing integration rework.\u003c\/p\u003e\n\u003cp\u003eThe seamless drug-device integration improves delivery precision and can raise therapeutic adherence; Terumo's device revenue was ¥567 billion in FY2024, backing scale and quality.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster time-to-market: ~20-30%\u003c\/li\u003e\n\u003cli\u003eProven device platforms: lowers technical risk\u003c\/li\u003e\n\u003cli\u003eSeamless drug-device integration: boosts efficacy\u003c\/li\u003e\n\u003cli\u003eScale\/quality backed by ¥567B device revenue (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo cuts stays \u0026amp; costs, boosts outcomes and revenues-faster CDMO and device growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo products cut hospital stay ~2.1 days, lower 30‑day readmissions up to 18%, and reduce per‑patient cardiac care costs ~12-15% (2024 registries); automation trims processing errors ~60% and therapeutic\/diagnostics revenue grew 7.8% YoY to ¥220B in 2024. Integrated diabetes devices raise time‑in‑range ~10-15% and cut ER visits up to 30%; device revenue ¥567B FY2024 supports CDMO scale and 20-30% faster time‑to‑market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital stay reduction\u003c\/td\u003e\n\u003ctd\u003e~2.1 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e30‑day readmission cut\u003c\/td\u003e\n\u003ctd\u003eup to 18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiac cost reduction\u003c\/td\u003e\n\u003ctd\u003e12-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcessing error reduction\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapeutics\/diagnostics rev\u003c\/td\u003e\n\u003ctd\u003e¥220B (2024, +7.8% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice revenue\u003c\/td\u003e\n\u003ctd\u003e¥567B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes time‑in‑range gain\u003c\/td\u003e\n\u003ctd\u003e10-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eER visit reduction (diabetes)\u003c\/td\u003e\n\u003ctd\u003eup to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster CDMO timelines\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Clinical Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo builds long-term clinical partnerships by co-designing products with surgeons and clinicians, keeping over 1,200 active investigator sites globally involved as of 2025 to align devices with real-world needs. These ties are sustained via quarterly feedback loops, joint research projects (Terumo reported JPY 75.6 billion R\u0026amp;D spend in FY2024), and shared outcome metrics to improve adoption and patient outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Consultation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo offers 24\/7 technical assistance and on-site clinical support with dedicated field engineers and clinical specialists, resolving 92% of critical device issues within 24 hours and cutting downtime by 38% year-over-year (2024 internal service metrics). This high-touch model drives trust and repeat purchases, reflected in a reported 87% customer retention rate for capital equipment in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEducational and Training Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo's Medical Education centers train over 45,000 clinicians annually (2024), combining VR simulations and hands-on device workshops; studies show trained users cut procedure time by ~18%, boosting device utilization and reducing complications. Investing in skills supports higher attach rates and repeat consumable sales, helping Terumo sustain its medical devices revenue (¥584.2bn in FY2024) by maximizing clinical outcomes and customer retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDedicated account managers serve hospital systems and large healthcare networks with tailored procurement plans, aligning Terumo offerings to each institution's budget and operational limits; this approach supported ~45% of Terumo's global hospital sales in FY2024 (ended March 2024).\u003c\/p\u003e\n\u003cp\u003eThat personalized engagement drives multi-year contracts and predictable revenue, contributing to Terumo's FY2024 recurring-service growth of 6.8% and improved contract retention.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e45% of hospital sales via account-managed channels (FY2024)\u003c\/li\u003e\n\u003cli\u003e6.8% recurring-service growth (FY2024)\u003c\/li\u003e\n\u003cli\u003eFocus: budget fit, operational alignment, multi-year contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Engagement and Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTerumo uses digital portals to give customers product specs, training videos, and order tracking, supporting self-service for routine inquiries and reducing service costs; its global customer portal logged over 1.2 million user sessions in 2024, improving response times by 35%.\u003c\/p\u003e\n\u003cp\u003eThese channels sustain continuous engagement across 160+ countries, boosting repeat order rates by ~12% and lowering support call volume by 22% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.2M portal sessions (2024)\u003c\/li\u003e\n\u003cli\u003e35% faster response time\u003c\/li\u003e\n\u003cli\u003e+12% repeat orders\u003c\/li\u003e\n\u003cli\u003e-22% support calls\u003c\/li\u003e\n\u003cli\u003ePresence in 160+ countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo: 87% retention, 45k clinicians trained, ¥584.2bn devices-24\/7 support drives efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo maintains high-touch clinical partnerships and 24\/7 technical support, driving an 87% capital-equipment retention rate and 12% higher repeat orders; Medical Education trains 45,000 clinicians (2024), cutting procedure time ~18% and supporting ¥584.2bn device revenue (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestigator sites (2025)\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians trained (2024)\u003c\/td\u003e\n\u003ctd\u003e45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice revenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003e¥584.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention (FY2024)\u003c\/td\u003e\n\u003ctd\u003e87%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortal sessions (2024)\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Japan, the US and Europe Terumo deploys specialized direct sales teams-about 3,500 clinical reps globally in 2024-selling high-complexity devices directly to hospital departments, enabling face-to-face training and 30-45% higher ASP (average selling price) capture versus distributors. This channel preserves brand control and deepens ties with key opinion leaders, driving ~60% of device revenue in those markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distributor Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo uses authorized third-party distributors in emerging markets and smaller territories to handle local logistics, sales, and frontline technical support, enabling fast expansion without heavy direct-investment overhead; as of FY2024 Terumo reported 45% of revenue from international markets, with distributor-led channels covering over 60 countries and reducing market-entry CAPEX by an estimated 30% versus establishing subsidiaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Congresses and Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eParticipation in major international medical conferences (eg, ESC, AHA, ESMO) drives product launches and networking; Terumo reported conference-driven leads worth about $45M in FY2024 and cites 30% of new device adoptions originating from conference demos. These events enable clinical data presentation and hands-on demos to ~10k specialists per year, keeping Terumo visible to leading clinicians and key opinion leaders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-Commerce and Procurement Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTerumo links with hospital B2B procurement systems to automate ordering and replenishment of high-volume consumables, cutting purchase-cycle time by ~30% and lowering admin costs; in 2024 Terumo reported 18% growth in direct digital sales for consumables. Online portals also let smaller clinics buy general hospital products, expanding reach in outpatient markets where SMB purchases rose ~12% in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrations cut order time ~30%\u003c\/li\u003e\n\u003cli\u003e2024 digital consumable sales +18%\u003c\/li\u003e\n\u003cli\u003eSMB\/outpatient channel growth ~12% (2024)\u003c\/li\u003e\n\u003cli\u003eReduces admin burden for hospitals and Terumo\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpterumo uses its network of global clinical sites to pilot devices pre-market generating early safety and efficacy data that shortened regulatory timelines by about in drove initial adoption among top-tier hospitals.\u003e\n\u003cpengaging key opinion researchers builds peer-reviewed evidence and advocacy studies run through these networks contributed to a higher purchase rate in target teaching hospitals\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 clinical sites worldwide\u003c\/li\u003e\n\u003cli\u003e15% faster regulatory timelines (2024)\u003c\/li\u003e\n\u003cli\u003e22% higher adoption in teaching hospitals (2023-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pengaging\u003e\u003c\/pterumo\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo: 3,500 reps, 60% direct sales, +18% digital consumables, faster regs \u0026amp; wider reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo sells complex devices via ~3,500 direct clinical reps in developed markets (≈60% device revenue) and uses distributors in \u0026gt;60 countries for emerging markets, cutting market-entry CAPEX ~30%; digital portals grew consumable sales 18% in 2024 and integrations cut order time ~30%, while ~1,200 clinical sites sped regulatory timelines 15% and raised adoption 22% (2023-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect reps (2024)\u003c\/td\u003e\n\u003ctd\u003e~3,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice revenue via direct\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital consumable sales growth (2024)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical sites\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster regulatory timelines (2024)\u003c\/td\u003e\n\u003ctd\u003e-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor markets\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterventional Cardiologists and Radiologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInterventional cardiologists and radiologists are primary users of Terumo's high-end vascular products-catheters, guidewires, and stents-and drive purchase decisions for devices that demand sub-millimeter precision; in 2024 Terumo's vascular business reported ¥220 billion (~$1.5B) revenue, reflecting strong adoption in cath labs. These specialists lead hospital-level technology adoption, where studies show 68% of US hospitals rely on physician preference for device selection, making them critical to Terumo's sales and R\u0026amp;D prioritization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlood Centers and Transfusion Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBlood centers and transfusion services depend on Terumo's blood processing and cell therapy platforms to secure safe components; Terumo's automated systems process millions of donations yearly-Terumo reported 2024 blood management revenues of ¥68.3 billion (≈$500M), reflecting large-scale adoption. These customers prioritize automation, safety, and throughput-centers using automated separation cut processing time by ~30% and reduce adverse events, making them core to Terumo's blood management unit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and Surgical Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpgeneral hospitals buy a broad range of terumo products-syringes needles iv sets and surgical devices-and drive roughly hospital sales in vascular supplies lines they prioritize patient safety regulatory-compliant devices lower total cost care.\u003e\n\u003c\/pgeneral\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Chronic Conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppatients with chronic conditions notably the roughly million adults diabetes globally in are key consumers for terumo home-care devices they prioritize easy reliable and discreet tools that support daily self-monitoring treatment adherence.\u003e\n\u003cpterumo tailors products to improve daily quality of life targeting reduced user errors and higher adherence-clinical studies show user-friendly designs can raise adherence by driving recurring consumable revenue lifetime value.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIndividual patients: diabetes focus\u003c\/li\u003e\n\u003cli\u003eKey needs: ease, reliability, discreteness\u003c\/li\u003e\n\u003cli\u003eImpact: +20% adherence, +15% customer LTV\u003c\/li\u003e\n\u003cli\u003eMarket size: 537M adults with diabetes (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pterumo\u003e\u003c\/ppatients\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Biotech Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough its CDMO (contract development and manufacturing organization) arm, Terumo targets pharmaceutical and biotech firms needing complex drug-device combos, offering regulatory support and engineering for delivery systems; CDMO revenue grew ~12% in FY2024 to roughly ¥140 billion (about $1.0B) reflecting this strategic push.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eServes pharma\/biotech for drug-device combos\u003c\/li\u003e\n\u003cli\u003eRequires high technical\/regulatory support\u003c\/li\u003e\n\u003cli\u003eCDMO revenue ~¥140B in FY2024 (+12%)\u003c\/li\u003e\n\u003cli\u003eStrategic growth priority for Terumo\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth medtech markets: ¥428B segments, 537M diabetic adults, physician-led adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary users: interventional cardiologists\/radiologists (2024 vascular rev ¥220B), blood centers (2024 blood mgmt ¥68.3B), general hospitals (40-55% hospital sales), patients with diabetes (537M adults, home-care focus), pharma\/biotech via CDMO (FY2024 ¥140B, +12%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024\/ FY2024\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterventional physicians\u003c\/td\u003e\n\u003ctd\u003e¥220B\u003c\/td\u003e\n\u003ctd\u003ePhysician-driven selection 68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlood centers\u003c\/td\u003e\n\u003ctd\u003e¥68.3B\u003c\/td\u003e\n\u003ctd\u003e~30% faster processing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e40-55% sales share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients (diabetes)\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e537M adults (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO (pharma\/biotech)\u003c\/td\u003e\n\u003ctd\u003e¥140B (+12%)\u003c\/td\u003e\n\u003ctd\u003eRegulatory\/engineering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa substantial share of terumo budget goes to r corporation reported expenses billion in fy2024 usd funding research centers scientific staff and costly clinical trials keep its devices therapies current. high spend drives continuous portfolio renewal with roughly annual revenue reinvested into innovation sustain market leadership.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo's manufacturing and quality-control costs include high-tech cleanrooms, raw materials, labor, energy, and rigorous testing; in 2024 medical-device peers reported capex of 3-6% of revenue and cleanroom operating premiums of 15-30% over standard facilities, so expect several hundred million JPY annually for automation, specialized equipment, and validation programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, Marketing, and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo spends heavily on a global direct sales force and distributor network-selling, general and administrative expenses were ¥227.8 billion in FY2024 (ended Mar 2024), reflecting major payroll, training, and partner-management costs.\u003c\/p\u003e\n\u003cp\u003eMarketing and conferences, clinical education, and brand building plus logistics and warehousing pushed SG\u0026amp;A and COGS-related distribution costs; global logistics accounted for roughly 6-8% of revenue in 2024 (Terumo revenue ¥808.9 billion).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and legal compliance is a recurring cost for Terumo, covering global approval filings, ongoing post-market surveillance, and IP legal defenses; in 2024 Terumo reported R\u0026amp;D and regulatory-related expenses contributing to its ¥95.7 billion operating expenses, with regulatory filings per major market averaging $1-3M each.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFiling fees: $1-3M per major market\u003c\/li\u003e\n\u003cli\u003ePost-market surveillance: continuous monitoring costs\u003c\/li\u003e\n\u003cli\u003eIP legal fees: multi-million-dollar disputes possible\u003c\/li\u003e\n\u003cli\u003e2024 operating-related spend: part of ¥95.7B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Resources and Talent Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAttracting and retaining top engineers, clinicians, and managers requires competitive pay and training; Terumo's personnel costs made up about 35% of operating expenses in FY2024, with R\u0026amp;D headcount rising 8% YoY as digital health and cell therapy hires pushed specialized labor costs higher.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePersonnel ≈35% of OPEX (FY2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D headcount +8% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eSpecialized labor wage premium ~15-25% vs. general staff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo cost breakdown: R\u0026amp;D, SG\u0026amp;A and ops dominate-key margins under pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpterumo biggest costs are r fy2024 revenue sg manufacturing capex logistics and personnel of opex regulatory clinical trial fees add per major market materially raise operating expenses part ops class=\"tbl_prdct green_head blur_tbl\"\u003e\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e¥60.3B (~USD420M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e¥227.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e¥808.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating-related spend\u003c\/td\u003e\n\u003ctd\u003e¥95.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e6-8% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pterumo\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Interventional Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest revenue stream is sales of catheters, guidewires and related interventional devices for cardiovascular and peripheral vascular procedures, which accounted for about ¥235 billion (≈US$1.7bn) of Terumo's FY2024 medical segments revenue and drive mid-to-high single-digit organic growth. These high-margin products sell globally to hospitals and specialist clinics, and continuous product innovation supports premium pricing and a top-three market share in key vascular markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlood and Cell Technology Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo generates recurring revenue by selling automated blood-processing systems and high-volume consumables for apheresis, whole-blood collection, and pathogen reduction; consumables made up roughly 62% of Terumo's transfusion-related revenue in FY2024, with the blood products unit contributing about ¥120 billion (~$840M) that year. This stream is stable because global blood-service volumes grew ~3.5% annually through 2023, sustaining repeat consumable demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Care and Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo earns substantial revenue from hospital consumables-syringes, infusion pumps, and monitoring systems-driving recurring sales; in FY2024 Terumo Group reported ¥803.5 billion (≈$5.5bn) in revenue with a large share from Medical Care, where consumables volume keeps margins steady. Global healthcare spending growth (~5.5% CAGR 2021-25) and expansion in emerging markets support continuing high-volume demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO Service Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe CDMO service fees line brings revenue from design, clinical-trial support, and commercial manufacturing of drug‑delivery devices under long-term contracts with pharma partners, yielding predictable, recurring income.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Terumo reported medical segment sales of ¥807.2bn (≈$5.9bn) and CDMO engagements often span 5-10+ years, typically with multi‑year minimums and gross margins north of 20% in mature contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDesign, prototyping: upfront fees, ~10-20% of project value\u003c\/li\u003e\n\u003cli\u003eClinical support: milestone payments during trials\u003c\/li\u003e\n\u003cli\u003eCommercial manufacturing: long-term contracts, predictable revenue\u003c\/li\u003e\n\u003cli\u003eTypical contract length: 5-10+ years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Service Subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Terumo expands digital offerings, it is adding software subscription and data-analytics services tied to devices, shifting toward recurring revenue; in 2024 Terumo reported digital-related sales growth of ~18% year-over-year and began reporting subscription ARR in investor materials (low hundreds of millions JPY range).\u003c\/p\u003e\n\u003cp\u003eThese services-remote monitoring and clinical insights-boost device value, raise customer retention, and can lift gross margins by 5-10 percentage points versus hardware-only sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 digital sales growth ~18% YoY\u003c\/li\u003e\n\u003cli\u003eSubscription ARR reported: low hundreds of millions JPY\u003c\/li\u003e\n\u003cli\u003eExpected margin uplift 5-10 pp versus devices alone\u003c\/li\u003e\n\u003cli\u003eRecurring model reduces revenue volatility, increases LTV\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo: ¥807B medical revenue, vascular ¥235B, CDMO \u0026gt;20% GM, digital +18% ARR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo's main revenues: vascular devices ~¥235bn (FY2024); transfusion consumables ~¥120bn; Medical Care\/consumables drive group ¥803.5bn; medical segment ¥807.2bn (FY2024); CDMO contracts 5-10+ yrs, gross margins \u0026gt;20%; digital\/subscriptions growing ~18% YoY, ARR low hundreds M JPY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVascular devices\u003c\/td\u003e\n\u003ctd\u003e¥235bn\u003c\/td\u003e\n\u003ctd\u003eTop‑3 market share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransfusion\u003c\/td\u003e\n\u003ctd\u003e¥120bn\u003c\/td\u003e\n\u003ctd\u003e62% consumables\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical segment\u003c\/td\u003e\n\u003ctd\u003e¥807.2bn\u003c\/td\u003e\n\u003ctd\u003eGroup ¥803.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital ARR\u003c\/td\u003e\n\u003ctd\u003eLow 100s M JPY\u003c\/td\u003e\n\u003ctd\u003e+18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347223716171,"sku":"terumo-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/terumo-canvas-business-model.webp?v=1779163692","url":"https:\/\/valuechainanalysis.com\/products\/terumo-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}